NCT05073848

Brief Summary

This is an investigation of possible relationships between daily physical activity (PA) and different measurements of fatigue in cancer survivors participating in a cancer exercise program.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P50-P75 for all trials

Timeline
1mo left

Started Oct 2021

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress99%
Oct 2021Jun 2026

First Submitted

Initial submission to the registry

July 22, 2021

Completed
3 months until next milestone

First Posted

Study publicly available on registry

October 12, 2021

Completed
8 days until next milestone

Study Start

First participant enrolled

October 20, 2021

Completed
4.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2026

Last Updated

July 8, 2025

Status Verified

July 1, 2025

Enrollment Period

4.6 years

First QC Date

July 22, 2021

Last Update Submit

July 2, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • 10-point Fatigue Scale, Day

    Severity of fatigue experienced over the course of the day, ranked 0-10. How would you rate your fatigue, over the last day, on a scale of 0-10, with 0 being no fatigue and 10 being the worst possible fatigue?

    3 months

  • Physical Activity measure by Actigraph device

    PA will be monitored using commonly used, non-invasive Actigraph devices (Actigraph GT3XP). Data will be collected utilizing methodology similar to that of the National Health and Nutrition Examination Survey (NHANES), in cancer survivors. The collected accelerometry data will be downloaded and analyzed in ActiLife software, calculation the average time spent in moderate-to-vigorous (MVPA) at each assessment period using standard algorithms and cut-points.

    3 months

Secondary Outcomes (1)

  • Physical assessment measures from BfitBwell Program

    3 months

Other Outcomes (1)

  • Response Rate to EMA assessments

    3 months

Study Arms (1)

BfitBwell Participants

Individuals in the BfitBwell Cancer Exercise Program complete a FACIT-Fatigue questionnaire at their baseline assessment. This will be screened for all incoming BfitBwell participants and those meeting the inclusion criteria of a score of 48 or less will be approached for interest in participating. The primary research activities beyond recruitment, screening, and informed consent are the collection of EMA fatigue assessments via smartphone application and PA assessment via actigraphy.

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

We will enroll 50-150 cancer survivors participating in the BfitBwell Cancer Exercise Program. As this is a non-invasive, exploratory observational investigation, there are minimal inclusion and exclusion criteria.

You may qualify if:

  • Be an active participant in the BfitBwell Cancer Exercise Program
  • Criteria for this program include:
  • Adult (\>= 18 years old)
  • Being a patient seen at the University of Colorado Cancer Center
  • Currently receiving cancer therapy or be within 6 months of completing cancer therapy
  • Have a signed physician clearance form to participate in an exercise program
  • Have a smartphone (necessary for the EMA assessments)
  • A score of 48 or less on the FACIT-Fatigue (completed during the initial BfitBwell Program assessment)
  • The minimally important difference of the FACIT-Fatigue is 3 points, suggesting that a score of at most 48 indicates the presence of CRF and allows for meaningful change in both directions.

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Colorado Cancer Center

Aurora, Colorado, 80045, United States

RECRUITING

Study Officials

  • Ryan Marker, PhD, PT

    University of Colorado, Denver

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 22, 2021

First Posted

October 12, 2021

Study Start

October 20, 2021

Primary Completion (Estimated)

June 1, 2026

Study Completion (Estimated)

June 1, 2026

Last Updated

July 8, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations